942-70-1

Basic information

• Product Name: 2-AMINO-5-(4-FLUOROPHENYL)-1 3 4-THIADI&
• Synonyms: 2-AMINO-5-(4-FLUOROPHENYL)-1 3 4-THIADI&;1,3,4-Thiadiazol-2-amine, 5-(4-fluorophenyl)-;5-(4-fluorophenyl)-1,3,4-thiadiazol-2-amine(SALTDATA: FREE);5-(4-Fluorophenyl)-1,3,4-thiadiazol-2-amine, 1-(5-Amino-1,3,4-thiadiazol-2-yl)-4-fluorobenzene;2-Amino-5-(4-fluorophenyl)-1,3,4-thiadiazole 97%
• CAS NO: 942-70-1
• Molecular Formula: C₈H₆FN₃S
• Molecular Weight: 195.22
• Product Categories: API intermediates;Building Blocks;Chemical Synthesis;Fluorinated Building Blocks;Heterocyclic Building Blocks;Heterocyclic Fluorinated Building Blocks;Other Fluorinated Heterocycles;Thiadiazoles
• Mol File: 942-70-1.mol
• Article Data: 39

Chemical Properties

• Melting Point: 238-243 °C
• Boiling Point: 351.9 °C at 760 mmHg
• Flash Point: 166.6 °C
• Appearance: /
• Density: 1.423 g/cm³
• Vapor Pressure: 3.98E-05mmHg at 25°C
• Refractive Index: 1.643
• CAS DataBase Reference: 2-AMINO-5-(4-FLUOROPHENYL)-1 3 4-THIADI&(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-(4-FLUOROPHENYL)-1 3 4-THIADI&(942-70-1)
• EPA Substance Registry System: 2-AMINO-5-(4-FLUOROPHENYL)-1 3 4-THIADI&(942-70-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 942-70-1(Hazardous Substances Data)

Usage

Uses

2-Amino-5-(4-fluorophenyl)-1,3,4-thiadiazole can be used as a substrate in the preparation of:Bithiophene based azo dyes with possible nonlinear optical (NLO) properties.4-Thiazolidinone derivatives as potent HCV NS5B polymerase inhibitors.1,3,4-Thiadiazole and phenothiazine hybrids as possible antitubercular agents.

InChI:InChI=1/C8H6FN3S/c9-6-3-1-5(2-4-6)7-11-12-8(10)13-7/h1-4H,(H2,10,12)

Upstream product

• 831-38-9 2-(4-fluorobenzoyl)hydrazinecarbothioamide 
• 459-38-1 (4-fluorobenzylidenehydrazinyl)thiocarboxamide 
• 456-22-4 4-Fluorobenzoic acid 
• 79-19-6 thiosemicarbazide 
• 459-57-4 4-fluorobenzaldehyde 
• 333-20-0 potassium thioacyanate 
• 2290-65-5 trimethylsilyl isothiocyanate 
• 456-06-4 4-fluorobenzoyl hydrazide 
• 403-33-8 methyl 4-flurobenzoate 
• 403-43-0 4-fluorobenzoyl chloride 

Downstream Products

• 70038-88-9 N-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-benzamidine 
• 70038-95-8 N-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-acetamidine 
• 980-45-0 4-acetylamino-N-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-benzenesulfonamide 
• 128627-65-6 (E)-N-[5-(4-Fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-3-phenyl-acrylamide 
• 128627-54-3 N-<5-(4-Fluorophenyl)-1,3,4-thiadiazol-2-yl>acrylamide 
• 128627-71-4 3-[5-(4-Fluoro-phenyl)-[1,3,4]thiadiazol-2-ylamino]-2-methyl-propionic acid 
• 128627-61-2 N-[5-(4-Fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-2-methyl-acrylamide 
• 91660-21-8 2-chloro-5-(4-fluorophenyl)-1,3,4-thiadiazole 
• 276254-79-6 2-(4-fluoro-phenyl)-5-methylsulfanyl-[1,3,4]thiadiazole 
• 108413-72-5 2-mercapto-5-(4-fluorophenyl)-1,3,4-thiadiazole 
• 852-39-1 4-amino-N-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-benzenesulfonamide 
• 1059-01-4 N-{4-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-ylsulfamoyl]-phenyl}-succinamic acid 
• 863-97-8 N-{4-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-ylsulfamoyl]-phenyl}-phthalamic acid 
• 1032462-66-0 5-(aminosulfonyl)-2-chloro-N-[5-(4-fluorophenyl)-1,3,4-thiadiazol-2-yl]benzamide 

Relevant articles and documents

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

N-(5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound

The invention belongs to the technical field of medicines, relates to a compound with antitumor activity and a specific chemical structure, and in particular relates to an N-((6, 7-dimethoxyquinoline-4-yl) oxy) methyl)-N-(5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound and a preparation method and an application thereof. The structural general formula of the compound is shown in the specification, wherein an R group is mono-substituted or double-substituted phenyl, fluorophenyl, chlorphenyl, bromophenyl, benzyl, benzyloxy, benzene nitro or trifluoromethyl substituted at 2-position, 3-position or 4-position. Pharmacological studies show that the compound provided by the invention has a relatively remarkable proliferation inhibition effect on HER-2 positive breast cancer cells SK-Br-3, the effect is obviously superior to that of HER-2 negative breast cancer cells MCF-7, the compound can be used for preparing antitumor drugs, and a new way is opened up for deep research and development of tumor drugs in the future. The preparation method provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.

Novel fatty acid-thiadiazole derivatives as potential antimycobacterial agents

The discovery of antibiotics around the middle twentieth century led to a decrease in the interest in antimycobacterial fatty acids. In order to re-establish the importance of naturally abundant fatty acid, a series of fatty acid-thiadiazole derivatives were designed and synthesized based on molecular hybridization approach. In vitro antimycobacterial potential was established by a screening of synthesized compounds against Mycobacterium tuberculosis H37Rv strain. Among them, compounds 5a, 5d, 5h, and 5j were the most active, with compound 5j exhibiting minimum inhibitory concentration of 2.34?μg/ml against M.tb H37Rv. Additionally, the compounds were docked to determine the probable binding interactions and understand the mechanism of action of most active molecules on enoyl-acyl carrier protein reductases (InhA), which is involved in the mycobacterium fatty acid biosynthetic pathway.